IP Verse

Combination Of A Pd-1 Antagonist And Eribulin For Treating Cancer - EP3265122

The patent EP3265122 was granted to Eisai R&D Management on May 4, 2022. The application was originally filed on Mar 3, 2016 under application number EP16710891A. The patent is currently recorded with a legal status of "Revoked".

EP3265122

EISAI R&D MANAGEMENT
Application Number
EP16710891A
Filing Date
Mar 3, 2016
Status
Revoked
Sep 12, 2023
Grant Date
May 4, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKFeb 3, 2023ELKINGTON AND FIFEADMISSIBLE
PAJAROFeb 3, 2023BIRD & BIRDADMISSIBLE
KONIG SZYNKA TILMANN VON RENESSEJan 23, 2023KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORFADMISSIBLE
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBJan 18, 2023WICHMANNADMISSIBLE

Patent Citations (36) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2011271358
DESCRIPTIONUS4816567
DESCRIPTIONUS6214865
DESCRIPTIONUS6329511
DESCRIPTIONUS7488802
DESCRIPTIONUS7521051
DESCRIPTIONUS7982060
DESCRIPTIONUS8008449
DESCRIPTIONUS8093410
DESCRIPTIONUS8168757
DESCRIPTIONUS8350067
DESCRIPTIONUS8354509
DESCRIPTIONUS8383796
DESCRIPTIONWO2004004771
DESCRIPTIONWO2004056875
DESCRIPTIONWO2004072286
DESCRIPTIONWO2008156712
DESCRIPTIONWO2010027827
DESCRIPTIONWO2010077634
DESCRIPTIONWO2011066342
DESCRIPTIONWO2012135408
DESCRIPTIONWO2013019906
DESCRIPTIONWO2014100079
INTERNATIONAL-SEARCH-REPORTWO2014087230
INTERNATIONAL-SEARCH-REPORTWO2014159562
INTERNATIONAL-SEARCH-REPORTWO2015112900
INTERNATIONAL-SEARCH-REPORTWO2015134605
OPPOSITIONUS2015246033
OPPOSITIONWO2012119077
OPPOSITIONWO2014087230
OPPOSITIONWO2014159562
OPPOSITIONWO2014199294
OPPOSITIONWO2015112900
OPPOSITIONWO2015134605
OPPOSITIONWO2015183961
OPPOSITIONWO2016141209

Non-Patent Literature (NPL) Citations (61) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- EMMETT V. SCHMIDT ET AL, "Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials", JAMA NETWORK OPEN, (20200205), vol. 3, no. 2, doi:10.1001/jamanetworkopen.2019.20833, page e1920833, XP055749245
EXAMINATION- TOLANEY S ET AL, "Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer", EUROPEAN JOURNAL OF CANCER, (20170128), vol. 72, doi:10.1016/S0959-8049(17)30131-4, ISSN 0959-8049, page S16, XP029912178
EXAMINATION- S M Tolaney ET AL, "Abstract PD6-13: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer | Cancer Research", Cancer Research, doi:10.1158/1538-7445.SABCS17-PD6-13, (20171205), URL: https://cancerres.aacrjournals.org/content/78/4_Supplement/PD6-13, (20201111), XP055749240
OPPOSITION- Anonymous, "A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Canc 021/KEYNOTE-021) ", Clinical Trials, NCT02039674, (20150225), pages 1 - 6, XP093026761
OPPOSITION- Anonymous, "A Study of Pembrolizumab ( MK -3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer ( MK -3475- 021/KEYNOTE-021", CLINICALTRIALS.GOV ARCHIVE NCT02039674, (20140217), pages 1 - 5, CLINICALTRIALS.GOV ARCHIVE NCT02039674, (20220614), XP055931009
OPPOSITION- Anonymous, "A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023) NCT02036502", ClinicalTrials.gov NCT02036502, (20140115), pages 1 - 15, ClinicalTrials.gov NCT02036502, URL: https://clinicaltrials.gov/ct2/show/NCT02036502, (20230224), XP093026759
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION for KEYTRUDA", MSD International GmbH, County Cork, Ireland, (20140901), pages 1 - 16, XP093018862
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION for KEYTRUDA", MSD International GmbH, County Cork, Ireland, (20140901), XP093018862
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION, HALAVEN® (eribulin mesylate)", JCN Newswire, Japan Corporate News Network, Singapore, Singapore, (20160212), pages 1 - 22, XP093018821
OPPOSITION- Anonymous, "History Changes for Study: NCT02331368 Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma", CLINICALTRIALS.GOV ARCHIVE NCT02331368, (20150101), pages 1 - 4, CLINICALTRIALS.GOV ARCHIVE NCT02331368 , (20220614), XP055931028
OPPOSITION- Anonymous, "History of Changes for Study: NCT01848834", ClinicalTrials.gov, (20150409), pages 1 - 2, ClinicalTrials.gov, URL: https://clinicaltrials.gov/ct2/history/NCT01848834?V33=View#StudyPageTop, (20211119), XP055863564
OPPOSITION- Anonymous, "Meeting Reporter at 37th Annual San Antonio Breast Cancer Symposium", Oncology Times, Independent News on hematology / Oncology, (20150210), pages 1 - 3, XP093028135
OPPOSITION- Anonymous, "Merck Announces Generic Name for MK-3475, Merck's Investigational anti-PD-1 Antibody: Pembrolizumab ", Merck, WHITEHOUSE STATION, N.J, WHITEHOUSE STATION, N.J, (20140530), pages 1 - 2, XP093026482
OPPOSITION- Anonymous, "Merck Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy", Merck, (20140904), pages 1 - 3, XP093028131
OPPOSITION- Anonymous, "Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer (UVA-PC- PD101)", Clinical Trials, NCT02305186, (20141127), pages 1 - 9, XP093026764
OPPOSITION- Anonymous, "Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)", URL: https://clinicaltrials.gov/archive/NCT02142738/2014_05_19, (20170614), XP055381602
OPPOSITION- Anonymous, "Study of Pembrolizumab (MK-3475) in participants with advanced solid tumors", ClinicalTrials.gov Identifier: NCT01848834, (20130508), pages 1 - 13, ClinicalTrials.gov Identifier: NCT01848834, URL: https://clinicaltrials.gov/ct2/show/NCT01848834, (20211102), XP055857256
OPPOSITION- Anonymous, "Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE- 086) ", Clinical Trials, NCT02447003, (20150514), pages 1 - 10, XP093026599
OPPOSITION- Anonymous, "Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) NCT02513472", ClinicalTrials.gov NCT02513472, (20220406), pages 1 - 14, ClinicalTrials.gov NCT02513472, URL: https://clinicaltrials.gov/ct2/show/NCT02513472, (20230223), XP093026493
OPPOSITION- Anonymous, "Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)", Clinical Trial, NCT02513472, (20151112), pages 1 - 7, XP093026609
OPPOSITION- Anonymous, "Top 8 Highlights From SABCS 2014", 2014 San Antonio Breast Cancer Symposium, (20141219), pages 1 - 3, XP093026732
OPPOSITION- Anonymous, "U.S. FDA APPROVES EISAI'S HALAVEN™ (ERIBULIN MESYLATE) INJECTION FOR TREATMENT OF METASTATIC BREAST CANCER", News Release Eisai, Eisai, (20101116), no. 10-64, pages 1 - 2, XP093028123
OPPOSITION- Anonymous, "WHO Drug Information Quality and Safety of Medicines Safety and Efficacy Issues The International Pharmacopoeia Contents", WHO Drug Information, (20130101), pages 95 - 134, WHO Drug Information, URL: https://apps.who.int/iris/bitstream/handle/10665/331168/DI272-eng.pdf?sequence=1&isAllowed=y, (20230223), XP093026492
OPPOSITION- Azvolinsky Anna, "Immunotherapy Yields Response in Triple-Negative Breast Cancer", San Antonio Breast Cancer Symposium (SABCS), (20141211), pages 1 - 3, XP093026728
OPPOSITION- Brewster Abenaa M, Et Al, "Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry", oncology, (20141201), vol. 15, pages e625 - e634, XP093026500
OPPOSITION- Eisai Public Relations Department, "Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer", Tokyo, Japan and Kenilworth, NJ, USA, Tokyo, Japan and Kenilworth, NJ, USA , (20150304), URL: http://www.eisai.com/news/enews201518pdf.pdf, (20160420), XP055267293
OPPOSITION- EISAI PUBLIC RELATIONS DEPARTMENT, "Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor", Multiple Types of Cancer, (20150304), URL: http://www.eisai.com/news/enews201518pdf.pdf, XP055267293
OPPOSITION- Kaufman Peter, Et Al, "Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): A pooled analysis by HER2 and ER status. ", Journal of Clinical Oncology, (20140101), pages 1 - 4, Journal of Clinical Oncology, URL: https://ascopubs.org/doi/abs/10.1200/jco.2014.32.26_suppl.137, (20230224), XP093026765
OPPOSITION- Morikawa Aki, "Treating Triple-Negative Breast Cancer: Where Are We?", Journal of the National Comprehensive Cancer Network, (20150101), vol. 13, no. 2, pages e8 - e18, XP093026497
OPPOSITION- Nanda R, Et Al, "A phase lb study of pembrolizumab ( MK -3475) in patients with advanced triple-negative breast cancer", San Antonio Breast Cancer Symposium, (20140101), pages 1 - 1, XP093026521
OPPOSITION- Nanda Rita et al, "A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer", San Antonio Breast Cancer Symposium, (20140101), page S1-09, XP093026491
OPPOSITION- "Pembrolizumab shows potential in breast cancer.", CANCER DISCOVERY, (20150201), vol. 5, no. 2, ISSN 2159-8290, pages 100 - 101, XP002786483
OPPOSITION- Poole Raewyn M, "Pembrolizumab: First Global Approval", Drugs, (20140101), vol. 74, pages 1973 - 1981, XP093026517
OPPOSITION- ROBERT et al., "LBA - Pembrolizumab (pembro; MK -3475) for advanced melanoma: Randomized comparison of two dosing schedules", Annals of Oncology, (20140929), vol. 25, no. 5, pages 1 - 41, XP055632262
OPPOSITION- Vahdat, Et Al, "P5-20-04", Cancer Research, (20121215), vol. 72, no. 24, page 479s, XP093026591
OPPOSITION- Emmett V. Schmidt et al, "Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials", JAMA Network Open, American Medical Association, (20200205), vol. 3, no. 2, doi:10.1001/jamanetworkopen.2019.20833, page e1920833, XP055749245
OPPOSITION- David F. Mcdermott, Michael B. Atkins, "PD-1 as a potential target in cancer therapy", Cancer Medicine, Wiley, (20130721), doi:10.1002/cam4.106, ISSN 20457634, pages 662 - 673, XP055157252
OPPOSITION- David F. Mcdermott, Michael B. Atkins, "PD-1 as a potential target in cancer therapy", Cancer Medicine, Wiley, (20130721), doi:10.1002/cam4.106, ISSN 20457634, pages n/a - n/a, XP055157252
OPPOSITION- Brian D Lehmann, Jennifer A Pietenpol, "Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes", The Journal of Pathology, Longman, Hoboken, USA, Hoboken, USA, (20140101), vol. 232, no. 2, doi:10.1002/path.4280, ISSN 0022-3417, pages 142 - 150, XP055238780
OPPOSITION- Twelves Chris et al, "Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies", Breast Cancer Research and Treatment, Springer US, New York, New York, (20141201), vol. 148, no. 3, doi:10.1007/s10549-014-3144-y, ISSN 0167-6806, pages 553 - 561, XP093026487
OPPOSITION- TWELVES et al., "Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies", Breast Cancer res Treat, (20140000), vol. 148, pages 553 - 561, XP035429884
OPPOSITION- ROBERT, C. et al., "Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies", European Journal of Cancer, (20130000), vol. 49, no. 14, doi:10.1016/j.ejca.2013.07.001, pages 2968 - 2971, XP055632318
OPPOSITION- KALIMUTHO, M. et al., "Targeted therapies for triple-negative breast cancer: combating a stubborn disease", Trends in pharmacological sciences, vol. 36, no. 12, doi:10.1016/j.tips.2015.08.009, (20151101), pages 822 - 846, XP029339482
OPPOSITION- Tolaney S. et al, "Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer", European Journal of Cancer, Elsevier, Amsterdam NL, Amsterdam NL , (19000101), vol. 72, doi:10.1016/S0959-8049(17)30131-4, ISSN 0959-8049, XP029912178
OPPOSITION- DOLGIN, "Cancer's true breakthroughs", Nature Medicine, (20130600), vol. 19, no. 6, doi:10.1038/nm.3245, pages 660 - 663, XP055452540
OPPOSITION- MULLARD, "Learning from the 2012-2013 class of breakthrough therapies", Nature Reviews, (20131200), vol. 12, doi:10.1038/nrd4196, pages 891 - 893, XP055935185
OPPOSITION- Funahashi Yasuhiro et al, "Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models", CANCER SCIENCE, JAPANESE CANCER ASSOCIATION, TOKYO, JP, JP , (20141001), vol. 105, no. 10, doi:10.1111/cas.12488, ISSN 1347-9032, pages 1334 - 1342, XP093026581
OPPOSITION- S M Tolaney, Et Al., "Abstract PD6-13: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer | Cancer Research", Cancer Research, doi:10.1158/1538-7445.SABCS17-PD6-13, (20171205), Cancer Research, URL: https://cancerres.aacrjournals.org/content/78/4_Supplement/PD6-13, (20201111), XP055749240
OPPOSITION- Anonymous, "PD-1 Inhibitor Becomes “Breakthrough Therapy”", CANCER DISCOVERY, American Association for Cancer Research, US, US , (20130701), vol. 3, no. 7, doi:10.1158/2159-8290.CD-NB2013-074, ISSN 2159-8274, pages OF14 - OF14, XP055935187
OPPOSITION- Elizabeth A. Mittendorf, Anne V. Philips, Funda Meric-Bernstam, Na Qiao, Yun Wu, Susan Harrington, Xiaoping Su, Ying Wang, Ana M. Gonzalez-Angulo, Argun Akcakanat, Akhil Chawla, Michael Curran, Patrick Hwu, Padmanee Sharma, Jennifer K. Litton, Jeffrey J. Molldrem, Gheath Alatrash, "PD-L1 Expression in Triple-Negative Breast Cancer", Cancer Immunology Research, American Association for Cancer Research, US, US , (20140401), vol. 2, no. 4, doi:10.1158/2326-6066.CIR-13-0127, ISSN 2326-6066, pages 361 - 370, XP002756567
OPPOSITION- MITTENDORF et al., "PD-L 1 Expression in Triple-Negative Breast Cancer", American Association for Cancer Research, (20140000), doi:10.1158/2326-6066.CIR-13-0127, pages 361 - 370, XP002756567
OPPOSITION- Marmé Frederik, Schneeweiss Andreas, "Targeted Therapies in Triple-Negative Breast Cancer", BREAST CARE, S. KARGER AG, BASEL, CH, CH , (20150101), vol. 10, no. 3, doi:10.1159/000433622, ISSN 1661-3791, pages 159 - 166, XP093026509
OPPOSITION- DOLAN, D. E. et al., "PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy", Cancer Control, (20140000), vol. 21, no. 3, doi:10.1177/107327481402100308, pages 231 - 237, XP009514187
OPPOSITION- Dolan D.E, Gupta S., "PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy.", CANCER CONTROL, Moffitt Cancer Center & Research Institute H Lee, US, US , (20140701), vol. 21, no. 3, doi:10.1177/107327481402100308, ISSN 1073-2748, pages 231 - 237, XP009514187
OPPOSITION- DOHERTY, M. K. et al., "Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy", International Journal of Women's Health, (20150100), vol. 7, doi:10.2147/IJWH.S74462, page 47, XP055469466
OPPOSITION- Mark Doherty, Patrick Morris, "Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy", INTERNATIONAL JOURNAL OF WOMEN'S HEALTH, Dove Medical Press Ltd., GB, GB , (20150101), doi:10.2147/IJWH.S74462, ISSN 1179-1411, pages 47 - 58, XP055469466
OPPOSITION- BAI et al., "A guide to rational dosing of monoclonal antibodies", Clin Pharmacokinet, (20120200), vol. 51, no. 2, doi:10.2165/11596370-000000000-00000, pages 119 - 35, XP009184175
OPPOSITION- Bai Shuang et al, "A Guide to Rational Dosing of Monoclonal Antibodies", CLINICAL PHARMACOKINETICS., ADIS INTERNATIONAL LTD., AUCKLAND, NZ, NZ , (20120101), vol. 51, no. 2, doi:10.2165/11596370-000000000-00000, ISSN 0312-5963, pages 119 - 135, XP009184175
OPPOSITION- Bruno Rosa, José Paulo De Jesus, Eduardo L De Mello, Daniel Cesar, Mauro M Correia, "Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis", ecancermedicalscience, Cancer Intelligence, (20151015), vol. 9, doi:10.3332/ecancer.2015.582, ISSN 1754-6605, XP055315738
OPPOSITION- REVIEW MANCINI, P. et al., "Standard of care and promising new agents for triple negative metastatic breast cancer", Cancers, (20140000), vol. 6, no. 4, doi:10.3390/cancers6042187, pages 2187 - 2223, XP055261923
OPPOSITION- Park Youngjin et al, "Clinical Benefits of and Recent Progress in Eribulin Mesylate Therapy for Breast Cancer Patients", Journal of Tumor, (20140101), vol. 2, doi:10.6051/j.issn.1819-6187.2014.02.25, pages 113 - 121, XP093026584

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents